Efficacy and safety results of telotristat ethyl in patients With carcinoid syndrome during the double-blind treatment period of the TELECAST phase 3 clinical trial.
dc.contributor.author | Pavel, M | |
dc.contributor.author | Gross, D | |
dc.contributor.author | Benavent, M | |
dc.contributor.author | Caplin, M | |
dc.contributor.author | Perros, P | |
dc.contributor.author | Srirajaskanthan, R | |
dc.contributor.author | Valle, Juan W | |
dc.contributor.author | Warner, R | |
dc.contributor.author | Kulke, M | |
dc.contributor.author | Anthony, L | |
dc.contributor.author | Kunz, P | |
dc.contributor.author | Horsch, D | |
dc.contributor.author | Berg, K | |
dc.contributor.author | Lapuerta, P | |
dc.contributor.author | Jackson, S | |
dc.contributor.author | Banks, P | |
dc.contributor.author | Biran, T | |
dc.contributor.author | Garcia-Carbonero, R | |
dc.date.accessioned | 2017-05-19T15:32:24Z | |
dc.date.available | 2017-05-19T15:32:24Z | |
dc.date.issued | 2017 | |
dc.identifier.citation | Efficacy and safety results of telotristat ethyl in patients With carcinoid syndrome during the double-blind treatment period of the TELECAST phase 3 clinical trial. 2017, 46(3): 434-435 Pancreas | en |
dc.identifier.uri | http://hdl.handle.net/10541/620380 | |
dc.language.iso | en | en |
dc.title | Efficacy and safety results of telotristat ethyl in patients With carcinoid syndrome during the double-blind treatment period of the TELECAST phase 3 clinical trial. | en |
dc.type | Meetings and Proceedings | en |
dc.contributor.department | Charité-Universitätsmedizin Berlin, CVK, Med. Klinik m. Schwerpunkt | en |
dc.identifier.journal | Pancreas | en |